In the latest trading session,, 245.43 million InMed Pharmaceuticals Inc (NASDAQ:INM) shares changed hands as the company’s beta touched 0.67. With the company’s most recent per share price at $0.52 changing hands around $0.37 or 252.72% at last look, the market valuation stands at $1.74M. INM’s current price is a discount, trading about -300.0% off its 52-week high of $2.08. The share price had its 52-week low at $0.12, which suggests the last value was 76.92% up since then. When we look at InMed Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.5 million shares, with the 3-month average coming to 1.42 million.
Analysts gave the InMed Pharmaceuticals Inc (INM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended INM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. InMed Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
InMed Pharmaceuticals Inc (NASDAQ:INM) trade information
Instantly INM is in green as seen in intraday trades today. With action 270.75%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 25.49%, with the 5-day performance at 270.75% in the green. However, in the 30-day time frame, InMed Pharmaceuticals Inc (NASDAQ:INM) is 95.15% up. Looking at the short shares, we see there were 0.25 million shares sold at short interest cover period of 0.12 days.
InMed Pharmaceuticals Inc (INM) estimates and forecasts
Year-over-year growth is forecast to reach 31.00% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 1.79M. The company’s revenue for the corresponding quarters a year ago was 2.31M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -22.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 39.17%.
INM Dividends
InMed Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2022-Sep-23.
InMed Pharmaceuticals Inc (NASDAQ:INM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.58% of InMed Pharmaceuticals Inc shares while 3.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.13%. There are 3.11% institutions holding the InMed Pharmaceuticals Inc stock share, with SABBY MANAGEMENT, LLC the top institutional holder. As of 2024-03-31, the company held 4.5366% of the shares, roughly 0.36 million INM shares worth $0.13 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 3.3482% or 0.27 million shares worth $97176.0 as of 2024-03-31.
With 556.0 shares estimated at $261.0 under it, the former controlled 0.01% of total outstanding shares.
